A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
about
Pharmacotherapies for obesity: past, current, and future therapiesSerotonin regulates C. elegans fat and feeding through independent molecular mechanismsEffects on weight reduction and safety of short-term phentermine administration in Korean obese peopleEffective management of obesityCombinations of drugs in the Treatment of Obesity.Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implicationsBody weight loss with phentermine alone versus phentermine and fenfluramine with very-low-calorie diet in an outpatient obesity management program: a retrospective studySafety of antiobesity drugs.Rise and fall of anti-obesity drugs.Serotonin receptors and heart valve disease--it was meant 2B.New pharmacological approaches for obesity management.The expanded biology of serotonin.Obesity drugs and their targets: correlation of mouse knockout phenotypes with drug effects in vivo.Pharmacotherapy for childhood obesity: present and future prospects.Comparative efficiency and safety of pharmacological approaches to the management of obesity.Hypothalamic obesity in patients with craniopharyngioma: treatment approaches and the emerging role of gastric bypass surgery.Central and peripheral neuroendocrine peptides and signalling in appetite regulation: considerations for obesity pharmacotherapy.Molecular neuroendocrine targets for obesity therapy.Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat.Recent advances in the pharmacological control of energy balance and body weight.The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour.Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.Gut hormone polyagonists for the treatment of type 2 diabetes.Combination pharmaceutical therapies for obesity
P2860
Q21296814-2CB3142A-FE67-4C1B-AD7D-90CCD4D9D404Q24649629-0D24536C-9ED1-467A-9267-B27C5E4AEF9AQ28201155-18F49405-3ABB-4819-989F-0E0C86EB93B5Q33578930-FD762303-5DEB-4258-9BF4-C8A751859859Q33664063-FC1448D4-FF47-4BCC-B3D8-6D6F0367B4D4Q33717424-01E6117B-B2CA-4882-86A4-28B18162B507Q33739051-05E51F08-EC0C-4B80-8F2F-151FC10F3850Q34016243-FF362FE7-C9D1-49ED-BC47-CE7E171FD2EDQ34026742-46BC6D1A-70B1-4C6F-814A-061440C5C132Q34173511-3EE0C8F3-CA87-4096-9F1A-920AE1244484Q34349850-1C6F8599-CEA1-45CB-9BEB-1286842EFD37Q34993925-E71E31D5-C850-4FB0-8AC0-681E137B969DQ36377258-8AF14F75-D8B2-4A05-B206-ABE4EEDE4926Q36468087-0C392341-68C2-4188-88E6-87E7613BA64CQ36783891-868C4E5B-E731-40A4-A9B1-1EC7C93FCA7AQ36810360-B51C7EDA-9B9C-4F1A-9E7E-04D6A82F2A0EQ37079243-4D922401-CE8B-44CB-8327-0609E670045BQ37569030-A4FAE3DF-740C-4D76-B915-6BA815453529Q38167630-6FCD01B9-8AAC-48AF-88AF-D198635985D4Q40482498-796ED7CA-5315-4918-8BB7-7372B875FF11Q41611336-0C89E14B-D4E2-4DFB-A475-2810376FAE40Q41910031-762805B7-C743-415D-A1D4-7C35D8A343F7Q43186384-4845BC73-9C0D-4012-9AC1-4BBAABC2A84BQ45140920-06CF4AE2-2322-437D-AE7B-11FFE63233AEQ49218095-8D11AC66-6BDA-41D9-90F5-1EC7FB3AAF3CQ57314317-9BBF84F4-08BE-41EE-AEF9-4D613F102971
P2860
A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
description
1984 nî lūn-bûn
@nan
1984 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
A double-blind clinical trial ...... mine alone and in combination.
@ast
A double-blind clinical trial ...... mine alone and in combination.
@en
A double-blind clinical trial ...... mine alone and in combination.
@nl
type
label
A double-blind clinical trial ...... mine alone and in combination.
@ast
A double-blind clinical trial ...... mine alone and in combination.
@en
A double-blind clinical trial ...... mine alone and in combination.
@nl
prefLabel
A double-blind clinical trial ...... mine alone and in combination.
@ast
A double-blind clinical trial ...... mine alone and in combination.
@en
A double-blind clinical trial ...... mine alone and in combination.
@nl
P2093
P1476
A double-blind clinical trial ...... mine alone and in combination.
@en
P2093
Lockwood DH
Mushlin AI
Weintraub M
P304
P356
10.1001/ARCHINTE.144.6.1143
P407
P577
1984-06-01T00:00:00Z